These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 26808136)
1. Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study. Okada S; Morimoto T; Ogawa H; Sakuma M; Soejima H; Nakayama M; Jinnouchi H; Waki M; Akai Y; Ishii H; Saito Y; PLoS One; 2016; 11(1):e0147635. PubMed ID: 26808136 [TBL] [Abstract][Full Text] [Related]
2. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y; Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185 [TBL] [Abstract][Full Text] [Related]
3. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T; Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565 [TBL] [Abstract][Full Text] [Related]
4. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study. Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575 [TBL] [Abstract][Full Text] [Related]
5. Association between dipstick hematuria and decline in estimated glomerular filtration rate among Japanese patients with type 2 diabetes: A prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 14)]. Mashitani T; Hayashino Y; Okamura S; Kitatani M; Furuya M; Iburi T; Tsujii S; Ishii H; J Diabetes Complications; 2017 Jul; 31(7):1079-1084. PubMed ID: 28499960 [TBL] [Abstract][Full Text] [Related]
6. Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. Matsumoto C; Ogawa H; Saito Y; Okada S; Soejima H; Sakuma M; Masuda I; Nakayama M; Doi N; Jinnouchi H; Waki M; Morimoto T; ; Diabetes Care; 2020 Feb; 43(2):314-320. PubMed ID: 31801787 [TBL] [Abstract][Full Text] [Related]
7. Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. Okada S; Morimoto T; Ogawa H; Sakuma M; Matsumoto C; Soejima H; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Saito Y; Diabetes Care; 2018 Aug; 41(8):1757-1764. PubMed ID: 29909377 [TBL] [Abstract][Full Text] [Related]
8. Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Gaede P; Hansen HP; Parving HH; Pedersen O Nephrol Dial Transplant; 2003 Mar; 18(3):539-42. PubMed ID: 12584276 [TBL] [Abstract][Full Text] [Related]
9. Renal effects of low dose aspirin in elderly patients. Segal R; Lubart E; Leibovitz A; Iaina A; Caspi D Isr Med Assoc J; 2006 Oct; 8(10):679-82. PubMed ID: 17125112 [TBL] [Abstract][Full Text] [Related]
10. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. Ishani A; Grandits GA; Grimm RH; Svendsen KH; Collins AJ; Prineas RJ; Neaton JD J Am Soc Nephrol; 2006 May; 17(5):1444-52. PubMed ID: 16611715 [TBL] [Abstract][Full Text] [Related]
11. Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. Violi F; Targher G; Vestri A; Carnevale R; Averna M; Farcomeni A; Lenzi A; Angelico F; Cipollone F; Pastori D Am Heart J; 2017 Jul; 189():120-127. PubMed ID: 28625368 [TBL] [Abstract][Full Text] [Related]
12. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH; Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640 [TBL] [Abstract][Full Text] [Related]
13. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
14. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608 [TBL] [Abstract][Full Text] [Related]
15. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Okada S; Morimoto T; Ogawa H; Kanauchi M; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sakuma M; Saito Y; Diabetes Care; 2011 Jun; 34(6):1277-83. PubMed ID: 21515838 [TBL] [Abstract][Full Text] [Related]
16. Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients. Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y; J Cardiol; 2020 Apr; 75(4):387-393. PubMed ID: 31564388 [TBL] [Abstract][Full Text] [Related]
17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651 [TBL] [Abstract][Full Text] [Related]
18. Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes. Fufaa GD; Weil EJ; Lemley KV; Knowler WC; Brosius FC; Yee B; Mauer M; Nelson RG Clin J Am Soc Nephrol; 2016 Feb; 11(2):254-61. PubMed ID: 26792530 [TBL] [Abstract][Full Text] [Related]
19. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851 [TBL] [Abstract][Full Text] [Related]
20. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]